Compare · KROS vs NVO
KROS vs NVO
Side-by-side comparison of Keros Therapeutics Inc. (KROS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KROS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 930.4x KROS ($231.6M).
- KROS has been more active in the news (10 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 22 for KROS).
- Company
- Keros Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $231.6M
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 10
- 9
- Recent ratings
- 22
- 25
Keros Therapeutics Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KROS
- Chief Legal Officer Cho Esther sold $46,151 worth of shares (4,485 units at $10.29), decreasing direct ownership by 11% to 35,770 units (SEC Form 4) to satisfy tax liability
- Director Newton Charles W. sold $5,675 worth of shares (551 units at $10.30) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 12,114 units (SEC Form 4)
- Chief Scientific Officer Lerner Lorena Raquel sold $36,715 worth of shares (3,568 units at $10.29), decreasing direct ownership by 11% to 27,559 units (SEC Form 4) (for withholding tax)
- Corp. Controller & VP, Finance Tanini Annita sold $12,595 worth of shares (1,224 units at $10.29), decreasing direct ownership by 3% to 45,144 units (SEC Form 4) (withholding tax)
- Director Bienaime Jean Jacques bought $10,270 worth of shares (1,000 units at $10.27), increasing direct ownership by 5% to 19,592 units (SEC Form 4)
- New insider Tanini Annita claimed ownership of 46,368 shares (SEC Form 3)
- Keros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Keros Therapeutics Inc.
- Keros Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Keros Therapeutics Reports Second Quarter 2026 Financial Results
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S